Clinical classification of memory and cognitive impairment with multimodal digital biomarkers

Abstract

INTRODUCTIONEarly detection of Alzheimer's disease and cognitive impairment is critical to improving the healthcare trajectories of aging adults, enabling early intervention and potential prevention of decline.METHODSTo evaluate multi‐modal feature sets for assessing memory and cognitive impairment, feature selection and subsequent logistic regressions were used to identify the most salient features in classifying Rey Auditory Verbal Learning Test‐determined memory impairment.RESULTSMultimodal models incorporating graphomotor, memory, and speech and voice features provided the stronger classification performance (area under the curve = 0.83; sensitivity = 0.81, specificity = 0.80). Multimodal models were superior to all other single modality and demographics models.DISCUSSIONThe current research contributes to the prevailing multimodal profile of those with cognitive impairment, suggesting that it is associated with slower speech with a particular effect on the duration, frequency, and percentage of pauses compared to normal healthy speech.

Performance Assessment of ChatGPT versus Bard in Detecting Alzheimer’s Dementia

“…Among AD subjects, GPT-3.5 demonstrates a broad range of MMSE scores (8-30) for correctly classified AD subjects yet predicts "Unsure" even for subjects with lower scores (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16). Additionally, it occasionally misclassifies AD subjects as CN for slightly higher MMSE scores (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25), which may be deemed reasonable.…”

“…Therefore, early screening and comprehensive understanding of Alzheimer's progression are paramount. Studies indicate that early interventions like lifestyle changes and social engagement could potentially slow down dementia progression, highlighting the criticality of early detection [4,5]. Despite pharmaceutical treatments being available, accurately assessing cognitive decline is imperative before initiating any intervention to mitigate disease advancement [6,7].…”